Research & Development



  “李文,王朝,邊通死定了。”   楊沖一臉的失望,正要拱手告辭的時候,又听梁翁道︰“雲氏若是將車馬售賣于楊氏,對其與勛貴不公,因此,可以將馬車當做禮物贈予楊氏,只限于唐氏大女乘坐。失禮之處,還請楊先生海涵!”人人看   只是,該怎麼帶著兩個女人一個嬰兒穿越數千里荒原最終回到大漢呢?人人操   “你還沒回答我的問題呢。” 人人摸   曹襄如同發現新大陸一般一躍而起,扯著雲瑯的袖子道︰“你今日去過了,我還沒去過呢,再去,再去。我知道你光顧的是老板娘,問題是你虧大了知道嗎?春風樓里的小甜美人只要笑起來,臉上就有兩只酒窩,天啊,我每次都要把酒倒在她的酒窩里才慢慢吸吮,你知道,脂粉香混著酒香一起下肚,這才是真正喝酒的模樣。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo